Novel therapeutic strategies for treating esophageal adenocarcinoma: The potential of dendritic cell immunotherapy and combinatorial regimens

Human Immunology

Volumn 69, Issue 10, 2008, Pages 614-624

  Milano, Francesca ^a   Krishnadath, Kausilia K ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Combinatorial treatment modalities; Cytotoxic T cell responses; Dendritic cells; Esophageal adenocarcinoma; Immunotherapy; Tumor microenvironment

Indexed keywords

BEVACIZUMAB; CELECOXIB; CISPLATIN; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; FLUOROURACIL; PACLITAXEL; TRASTUZUMAB; TUMOR ANTIGEN;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURGERY; CELL THERAPY; CLINICAL FEATURE; DENDRITIC CELL; DRUG MECHANISM; DRUG POTENTIATION; ESOPHAGEAL ADENOCARCINOMA; HUMAN; KIDNEY CARCINOMA; MICROENVIRONMENT; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; DRUG THERAPY, COMBINATION; ESOPHAGEAL NEOPLASMS; HUMANS; IMMUNOTHERAPY; RISK FACTORS; T-LYMPHOCYTES, REGULATORY;

EID: 54549097015     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2008.07.006     Document Type: Review

References (115)

1. Elton E. Esophageal cancer. Dis Mon 51 (2005) 664
2. Bohnenkamp H.R., Coleman J., Burchell J.M., Taylor-Papadimitriou J., and Noll T. Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers. Cell Immunol 231 (2004) 112
3. Bollschweiler E., Wolfgarten E., Gutschow C., and Holscher A.H. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 92 (2001) 549
4. Blot W.J., and McLaughlin J.K. The changing epidemiology of esophageal cancer. Semin Oncol 26 5 Suppl 15 (1999) 2
5. Wang J.M., Xu B., Rao J.Y., Shen H.B., Xue H.C., and Jiang Q.W. Diet habits, alcohol drinking, tobacco smoking, green tea drinking, and the risk of esophageal squamous cell carcinoma in the Chinese population. Eur J Gastroenterol Hepatol 19 (2007) 171
6. Weir H.K., Thun M.J., Hankey B.F., Ries L.A., Howe H.L., Wingo P.A., Jemal A., Ward E., Anderson R.N., and Edwards B.K. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95 (2003) 1276
7. Pera M. Trends in incidence and prevalence of specialized intestinal metaplasia, barrett's esophagus, and adenocarcinoma of the gastroesophageal junction. World J Surg 27 (2003) 999
8. Lee C.H., Lee J.M., Wu D.C., Hsu H.K., Kao E.L., Huang H.L., Wang T.N., Huang M.C., and Wu M.T. Independent and combined effects of alcohol intake, tobacco smoking and betel quid chewing on the risk of esophageal cancer in Taiwan. Int J Cancer 113 (2005) 475
9. Demeester S.R., Peters J.H., and Demeester T.R. Barrett's esophagus. Curr Probl Surg 38 (2001) 558
10. Spechler S.J., Zeroogian J.M., Antonioli D.A., Wang H.H., and Goyal R.K. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 344 (1994) 1533
11. Mann N.S., Tsai M.F., and Nair P.K. Barrett's esophagus in patients with symptomatic reflux esophagitis. Am J Gastroenterol 84 (1989) 1494
12. Drewitz D.J., Sampliner R.E., and Garewal H.S. The incidence of adenocarcinoma in Barrett's esophagus: A prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 92 (1997) 212
13. Flejou J.F. Barrett's oesophagus: From metaplasia to dysplasia and cancer. Gut 54 Suppl 1 (2005) i6
14. Krishnadath K.K. Novel findings in the pathogenesis of esophageal columnar metaplasia or Barrett's esophagus. Curr Opin Gastroenterol 23 (2007) 440
15. Barrett M.T., Sanchez C.A., Prevo L.J., Wong D.J., Galipeau P.C., Paulson T.G., Rabinovitch P.S., and Reid B.J. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 22 (1999) 106
16. Kimura T., Maesawa C., Ikeda K., Wakabayashi G., and Masuda T. Mutations of the epidermal growth factor receptor gene in gastrointestinal tract tumor cell lines. Oncol Rep 15 (2006) 1205
17. Koppert L.B., Wijnhoven B.P., van Dekken H., Tilanus H.W., and Dinjens W.N. The molecular biology of esophageal adenocarcinoma. J Surg Oncol 92 (2005) 169
18. Peracchia A., Bonavina L., Via A., and Incarbone R. Current trends in the surgical treatment of esophageal and cardia adenocarcinoma. J Exp Clin Cancer Res 18 (1999) 289
19. McDonough P.B., Jones D.R., Shen K.R., Northup P.G., Galysh R.L., Hernandez A., et al. Does FDG-PET add information to EUS and CT in the initial management of esophageal cancer?. A prospective single center study. Am J Gastroenterol 103 (2008) 570-574
20. Tseng E.E., Wu T.T., Yeo C.J., and Heitmiller R.F. Barrett's esophagus with high grade dysplasia: Surgical results and long-term outcome-an update. J Gastrointest Surg 7 (2003) 164
21. Gee D.W., and Rattner D.W. Management of gastroesophageal tumors. Oncologist 12 (2007) 175
22. Bergman J.J. Endoscopic resection for treatment of mucosal Barrett's cancer: Time to swing the pendulum. Gastrointest Endosc 65 (2007) 11
23. Sharma V.K., Wang K.K., Overholt B.F., Lightdale C.J., Fennerty M.B., Dean P.J., et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-Year follow-up of 100 patients. Gastrointest Endosc 65 (2007) 185
24. Prasad G.A., Wang K.K., Buttar N.S., Wongkeesong L.M., Krishnadath K.K., Nichols III F.C., et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology 132 (2007) 1226
25. Law S., Kwong D.L., Kwok K.F., Wong K.H., Chu K.M., Sham J.S., and Wong J. Improvement in treatment results and long-term survival of patients with esophageal cancer: Impact of chemoradiation and change in treatment strategy. Ann Surg 238 (2003) 339
26. Sihvo E.I., Luostarinen M.E., and Salo J.A. Fate of patients with adenocarcinoma of the esophagus and the esophagogastric junction: A population-based analysis. Am J Gastroenterol 99 (2004) 419
27. Arnott S.J., Duncan W., Gignoux M., Girling D.J., Hansen H.S., Launois B., et al. Preoperative radiotherapy in esophageal carcinoma: A meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group). Int J Radiat Oncol Biol Phys 41 (1998) 579
28. Cooper J.S., Guo M.D., Herskovic A., Macdonald J.S., Martenson Jr. J.A., Al-Sarraf M., et al. Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281 (1999) 1623
29. Minsky B.D., Pajak T.F., Ginsberg R.J., Pisansky T.M., Martenson J., Komaki R., et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol 20 (2002) 1167
30. Walsh T.N., Noonan N., Hollywood D., Kelly A., Keeling N., and Hennessy T.P. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335 (1996) 462
31. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5 (2005) 263
32. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., and Schreiber R.D. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 3 (2002) 991
33. Smyth M.J., Dunn G.P., and Schreiber R.D. Cancer immunosurveillance and immunoediting: The roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90 (2006) 1-50
34. Kim R., Emi M., and Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 121 (2007) 539-545
35. Dunn G.P., Old L.J., and Schreiber R.D. The three Es of cancer immunoediting. Annu Rev Immunol 22 (2004) 329
36. Balkwill F., and Mantovani A. Inflammation and cancer: Back to Virchow?. Lancet 357 (2001) 539
37. Cella M., Scheidegger D., Palmer-Lehmann K., Lane P., Lanzavecchia A., and Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184 (1996) 747
38. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245
39. Reis e Sousa C., Hieny S., Scharton-Kersten T., Jankovic D., Charest H., Germain R.N., and Sher A. In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas. J Exp Med 186 (1997) 1819
40. Caux C., Vanbervliet B., Massacrier C., Azuma M., Okumura K., Lanier L.L., and Banchereau J. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J Exp Med 180 (1994) 1841
41. Heath W.R., Belz G.T., Behrens G.M., Smith C.M., Forehan S.P., Parish I.A., Davey G.M., Wilson N.S., Carbone F.R., and Villadangos J.A. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 199 (2004) 9
42. Dzionek A., Fuchs A., Schmidt P., Cremer S., Zysk M., Miltenyi S., et al. BDCA-2, BDCA-3, and BDCA-4: Three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 165 (2000) 6037
43. Ito T., Amakawa R., Inaba M., Ikehara S., Inaba K., and Fukuhara S. Differential regulation of human blood dendritic cell subsets by IFNs. J Immunol 166 (2001) 2961
44. Koch F., Stanzl U., Jennewein P., Janke K., Heufler C., Kampgen E., et al. High level IL-12 production by murine dendritic cells: Upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med 184 (1996) 741
45. Rissoan M.C., Soumelis V., Kadowaki N., Grouard G., Briere F., de Waal Malefyt R., and Liu Y.J. Reciprocal control of T helper cell and dendritic cell differentiation. Science 283 (1999) 1183
46. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., and Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201 (2005) 233
47. Ueno H., Klechevsky E., Morita R., Aspord C., Cao T., Matsui T., et al. Dendritic cell subsets in health and disease. Immunol Rev 219 (2007) 118
48. Stumhofer J.S., Laurence A., Wilson E.H., Huang E., Tato C.M., Johnson L.M., et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol 7 (2006) 937
49. Kretschmer K., Apostolou I., Hawiger D., Khazaie K., Nussenzweig M.C., and von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 6 (2005) 1219
50. Jonuleit H., Schmitt E., Schuler G., Knop J., and Enk A.H. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192 (2000) 1213
51. Dhodapkar M.V., Steinman R.M., Krasovsky J., Munz C., and Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193 (2001) 233
52. Sallusto F., and Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179 (1994) 1109
53. Nencioni A., and Brossart P. Cellular immunotherapy with dendritic cells in cancer: Current status. Stem Cells 22 (2004) 501
54. Banchereau J., Schuler-Thurner B., Palucka A.K., and Schuler G. Dendritic cells as vectors for therapy. Cell 106 (2001) 271
55. Nouri-Shirazi M., Banchereau J., Fay J., and Palucka K. Dendritic cell based tumor vaccines. Immunol Lett 74 (2000) 5
56. Dhodapkar M.V., Krasovsky J., Steinman R.M., and Bhardwaj N. Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. J Clin Invest 105 (2000) R9
57. Muller M.R., Grunebach F., Kayser K., Vogel W., Nencioni A., Brugger W., Kanz L., and Brossart P. Expression of her-2/neu on acute lymphoblastic leukemias: Implications for the development of immunotherapeutic approaches. Clin Cancer Res 9 (2003) 3448
58. Brossart P., Wirths S., Brugger W., and Kanz L. Dendritic cells in cancer vaccines. Exp Hematol 29 (2001) 1247
59. Schuler G., Schuler-Thurner B., and Steinman R.M. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15 (2003) 138
60. Brossart P., Stuhler G., Flad T., Stevanovic S., Rammensee H.G., Kanz L., and Brugger W. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 58 (1998) 732
61. Fong L., and Engleman E.G. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18 (2000) 245
62. Tuting T., Wilson C.C., Martin D.M., Kasamon Y.L., Rowles J., Ma D.I., et al. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. J Immunol 160 (1998) 1139
63. Strobel I., Berchtold S., Gotze A., Schulze U., Schuler G., and Steinkasserer A. Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Gene Ther 7 (2000) 2028
64. Van Tendeloo V.F., Ponsaerts P., Lardon F., Nijs G., Lenjou M., Van Broeckhoven C., et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: Superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98 (2001) 49
65. Heiser A., Maurice M.A., Yancey D.R., Coleman D.M., Dahm P., and Vieweg J. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res 61 (2001) 3388
66. Hsu F.J., Benike C., Fagnoni F., Liles T.M., Czerwinski D., Taidi B., et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2 (1996) 52
67. Schuler-Thurner B., Schultz E.S., Berger T.G., Weinlich G., Ebner S., Woerl P., et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195 (2002) 1279
68. Banchereau J., Palucka A.K., Dhodapkar M., Burkeholder S., Taquet N., Rolland A., et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61 (2001) 6451
69. Smithers M., O'Connell K., MacFadyen S., Chambers M., Greenwood K., Boyce A., et al. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen. Cancer Immunol Immunother 52 (2003) 41
70. Butterfield L.H., Ribas A., Dissette V.B., Amarnani S.N., Vu H.T., Oseguera D., et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9 (2003) 998
71. Fong L., Brockstedt D., Benike C., Breen J.K., Strang G., Ruegg C.L., and Engleman E.G. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 167 (2001) 7150
72. Heiser A., Coleman D., Dannull J., Yancey D., Maurice M.A., Lallas C.D., et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109 (2002) 409
73. Holtl L., Zelle-Rieser C., Gander H., Papesh C., Ramoner R., Bartsch G., et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 8 (2002) 3369
74. O'Rourke M.G., Johnson M., Lanagan C., See J., Yang J., Bell J.R., et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 52 (2003) 387
75. Timmerman J.M., Czerwinski D.K., Davis T.A., Hsu F.J., Benike C., Hao Z.M., et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients. Blood 99 (2002) 1517
76. Milano F., Rygiel A.M., Buttar N., Bergman J.J., Sondermeijer C., van Baal J.W., et al. An ex vivo readout for evaluation of dendritic cell-induced autologous cytotoxic T lymphocyte responses against esophageal cancer. Cancer Immunol Immunother 56 (2007) 1967
77. Yang W., and Yu J. Immunologic function of dendritic cells in esophageal cancer. Dig Dis Sci 53 (2008) 1739-1746
78. Sadanaga N., Nagashima H., Mashino K., Tahara K., Yamaguchi H., Ohta M., et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 7 (2001) 2277
79. Yamana H. Immunotherapy for esophageal carcinoma]. Nippon Geka Gakkai Zasshi 103 (2002) 376
80. Loveland B.E., Zhao A., White S., Gan H., Hamilton K., Xing P.X., et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: A phase I trial in patients with adenocarcinoma. Clin Cancer Res 12 (2006) 869
81. Lin J., Lin L., Thomas D.G., Greenson J.K., Giordano T.J., Robinson G.S., et al. Melanoma-associated antigens in esophageal adenocarcinoma: Identification of novel MAGE-A10 splice variants. Clin Cancer Res 10 (2004) 5708
82. Rabinovich G.A., Gabrilovich D., and Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25 (2007) 267
83. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2 (1996) 1096
84. Allavena P., Piemonti L., Longoni D., Bernasconi S., Stoppacciaro A., Ruco L., and Mantovani A. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 28 (1998) 359
85. Menetrier-Caux C., Montmain G., Dieu M.C., Bain C., Favrot M.C., Caux C., and Blay J.Y. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: Role of interleukin-6 and macrophage colony-stimulating factor. Blood 92 (1998) 4778
86. Fallarino F., Grohmann U., You S., McGrath B.C., Cavener D.R., Vacca C., et al. The combined effects of tryptophan starvation and tryptophan catabolites downregulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 176 (2006) 6752
87. Mantovani A., Sozzani S., Locati M., Allavena P., and Sica A. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23 (2002) 549
88. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6 (2006) 295
89. Zhou G., and Levitsky H.I. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol 178 (2007) 2155
90. Barnett B., Kryczek I., Cheng P., Zou W., and Curiel T.J. Regulatory T cells in ovarian cancer: Biology and therapeutic potential. Am J Reprod Immunol 54 (2005) 369
91. Shimizu J., Yamazaki S., and Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: A common basis between tumor immunity and autoimmunity. J Immunol 163 (1999) 5211
92. Gabrilovich D.I., Bronte V., Chen S.H., Colombo M.P., Ochoa A., Ostrand-Rosenberg S., and Schreiber H. The terminology issue for myeloid-derived suppressor cells. Cancer Res 67 (2007) 425 author reply 426
93. Tuynman J.B., Buskens C.J., Kemper K., ten Kate F.J., Offerhaus G.J., Richel D.J., and van Lanschot J.J. Neoadjuvant selective COX-2 inhibition downregulates important oncogenic pathways in patients with esophageal adenocarcinoma. Ann Surg 242 (2005) 840
94. Traina T.A., Rugo H.S., and Dickler M. Bevacizumab for advanced breast cancer. Hematol Oncol Clin North Am 21 (2007) 303
95. von Rahden B.H., Stein H.J., Puhringer-Oppermann F., and Sarbia M. c-myc Amplification is frequent in esophageal adenocarcinoma and correlated with the upregulation of VEGF-A expression. Neoplasia 8 (2006) 702
96. Dahlberg P.S., Jacobson B.A., Dahal G., Fink J.M., Kratzke R.A., Maddaus M.A., and Ferrin L.J. ERBB2 amplifications in esophageal adenocarcinoma. Ann Thorac Surg 78 (2004) 1790
97. Ooi A., Takehana T., Li X., Suzuki S., Kunitomo K., Iino H., et al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: An immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 17 (2004) 895
98. Perez S.A., Sotiropoulou P.A., Sotiriadou N.N., Mamalaki A., Gritzapis A.D., Echner H., et al. HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones. Cancer Immunol Immunother 50 (2002) 615
99. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 1344 (2001) 783
100. Mimura K., Kono K., Hanawa M., Kanzaki M., Nakao A., Ooi A., and Fujii H. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 11 (2005) 4898
101. Kono K., Takahashi A., Sugai H., Fujii H., Choudhury A.R., Kiessling R., and Matsumoto Y. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res 8 (2002) 3394
102. Clemenceau B., Gallot G., Vivien R., Gaschet J., Campone M., and Vie H. Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy. J Immunother 29 (2006) 53
103. Kono K., Rongcun Y., Charo J., Ichihara F., Celis E., Sette A., et al. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer 78 (1998) 202
104. Kono K, Sato E, Naganuma H, Takahashi A, Mimura K, Nukui H, Fujii H. Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes. Clin Cancer Res 2994;10:2538.
105. Safran H., Dipetrillo T., Akerman P., Ng T., Evans D., Steinhoff M., et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 67 (2007) 405
106. Tew W.P., Kelsen D.P., and Ilson D.H. Targeted therapies for esophageal cancer. Oncologist 10 (2005) 590
107. Baselga J., Albanell J., Ruiz A., Lluch A., Gascon P., Guillem V., et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 23 (2005) 5323
108. Sutmuller R.P., van Duivenvoorde L.M., van Elsas A., Schumacher T.N., Wildenberg M.E., Allison J.P., et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194 (2001) 823
109. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (2004) 942
110. Dannull J., Su Z., Rizzieri D., Yang B.K., Coleman D., Yancey D., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115 (2005) 3623
111. Royer P.J., Bougras G., Ebstein F., Leveque L., Tanguy-Royer S., Simon T., et al. Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: Application to active immunotherapy. Exp Hematol 36 (2008) 329
112. Teitz-Tennenbaum S., Li Q., Rynkiewicz S., Ito F., Davis M.A., McGinn C.J., and Chang A.E. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res 63 (2003) 8466
113. Yu B., Kusmartsev S., Cheng F., Paolini M., Nefedova Y., Sotomayor E., and Gabrilovich D. Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clin Cancer Res 9 (2003) 285
114. Singh P., Uzgare A., Litvinov I., Denmeade S.R., and Isaacs J.T. Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr Relat Cancer 13 (2006) 653
115. Tokudome N., Ito Y., Hatake K., Toi M., Sano M., Iwata H., Sato Y., et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II and pharmacokinetic study in Japan. Anticancer Drugs 19 (2008) 753